Inflammatory cytokines and related pathways

Inflammatory cytokines and related pathways represent a broad therapeutic category comprising secreted signaling proteins and the intracellular signaling networks they activate to regulate immune responses. Key components include the tumor necrosis factor (TNF) superfamily, various interleukins (e.g., IL-1, IL-6, IL-12/23, IL-17), and interferons, which signal through pathways like JAK/STAT, NF-κB, and MAPK (PubMed, PMID: 31043915). These pathways are critical for coordinating innate and adaptive immunity; however, their dysregulation is central to the pathogenesis of chronic inflammatory conditions, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, as well as acute conditions like cytokine release syndrome (StatPearls, 2023). Pharmacological intervention is highly successful and includes monoclonal antibodies that neutralize ligands or receptors, and small-molecule inhibitors targeting downstream kinases. Despite their efficacy, targeting these pathways requires careful management due to the inherent risk of systemic immunosuppression and subsequent opportunistic infections (NIH, 2022).

Other names

Pro-inflammatory cytokinesInflammatory signaling pathwaysCytokine networkInflammatory mediators

Therapeutic agents modulate these pathways by neutralizing pro-inflammatory cytokine ligands, competitively inhibiting their cognate cell-surface receptors, or blocking intracellular signal transduction through the inhibition of kinases such as Janus kinases (JAKs), thereby preventing the transcription of inflammatory genes.